Who is sponsoring NCT03108300?

NCT03108300 is sponsored by Ain Shams University.

What drugs are being tested in NCT03108300?

Interventions in NCT03108300: Propranolol Hydrochloride, Doxorubicin.

What condition does NCT03108300 study?

NCT03108300 studies Malignant Soft Tissue Sarcoma.

Is NCT03108300 still recruiting?

NCT03108300 is currently status unknown. Last updated 23 February 2018.

Last reviewed 2018-02-23 · How we verify

NCT03108300

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Propranolol Hydrochloride in the Treatment of Metastatic STS

Status unknown Phase 2 Last updated 23 February 2018

What this trial tests

Phase 2 trial testing Propranolol Hydrochloride in Malignant Soft Tissue Sarcoma in 50 participants. Status unknown.

Timeline

30 August 2019

Primary endpoint
30 August 2020

30 August 2021

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	30 August 2019
Primary completion	30 August 2020
Estimated completion	30 August 2021

Drugs / interventions tested

Propranolol Hydrochloride — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →

Conditions studied

Malignant Soft Tissue Sarcoma — all drugs for Malignant Soft Tissue Sarcoma →

Sponsor

Ain Shams University

Who can join

19 and older, any sex, with Malignant Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fifty patients with pathological proof of malignant soft tissue sarcoma will receive Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily. * The primary end point : To assess Progression Free Survival (PFS) * The secondary end points : To assess Overall Survival (OS) and Toxicity Profile

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

The updated landscape of tumor microenvironment and drug repurposing.
Jin MZ, Jin WL. · · 2020 · cited 900× · PMID 32843638 · DOI 10.1038/s41392-020-00280-x
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, et al · · 2020 · cited 134× · PMID 33094495 · DOI 10.1002/ejhf.2029
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
Pu T, Sun J, Ren G, Li H. · · 2025 · cited 34× · PMID 40456735 · DOI 10.1038/s41392-025-02241-8
Trial watch: beta-blockers in cancer therapy.
Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2023 · cited 25× · PMID 38126031 · DOI 10.1080/2162402x.2023.2284486
Neuroscience in peripheral cancers: tumors hijacking nerves and neuroimmune crosstalk.
Fan HY, Liang XH, Tang YL. · · 2024 · cited 18× · PMID 39492832 · DOI 10.1002/mco2.784
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities.
Zhang C, Guo X, Liu P, Wang Y, et al · · 2025 · cited 6× · PMID 41152924 · DOI 10.1186/s13045-025-01748-5
The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response.
Manoleras AV, Sloan EK, Chang A. · · 2024 · cited 2× · PMID 39381049 · DOI 10.3389/fonc.2024.1460493

Verify or expand the search:

Other trials of Propranolol Hydrochloride

Trials testing the same drug.

NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
NCT06445166 — Propranolol for the Treatment of Kaposi Sarcoma in Adults · Phase 2 · recruiting
NCT05997732 — Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences · Phase 4 · recruiting
NCT05219799 — Sex Disparities in Hypoxic Vasodilation and Impact of Obesity · EARLY_PHASE1 · recruiting
NCT05651594 — Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanc · Phase 2 · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03108300 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 23 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03108300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing